KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP.;신태준;최선혜;건국대학교 산학협력단;NAH, Seung Yeol;CHOI, Sun Hye;HWANG, Sung Hee;SHIN, Tae Joon;황성희;나승열
发明人:
NAH, Seung Yeol,나승열,HWANG, Sung Hee,황성희,SHIN, Tae Joon,신태준,CHOI, Sun Hye,최선혜
申请号：
KRKR2012/007505
公开号：
WO2013/042943A3
申请日:
2012.09.19
申请国别(地区):
KR
年份:
2013
代理人:
摘要：
The present invention relates to glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medicinal-plant-derived ligand acting on LPA1(lysophosphatidic acid； 1- or 2-acyl-sn-glycerol-3-phosphate), LPA2, LPA3, LPA4 and LPA5 receptors whose efficacy is exhibited physiologically/pharmaceutically via an interaction with subset receptors [LPA1(edg-2), LPA2(edg-4), LPA3(edg-7), LPA4, PLA5] in the EDG (endothelial differentiation gene) family in G protein-coupled receptors (GPCRs) present in the cell membranes of animals including humans. The gintonin of the present invention can be used to advantage in the prevention and treatment of various diseases arising from reduced calcium concentration and various physiological activities and pharmaceutical activities dependent on calcium, since the gintonin of the present invention interacts with LPA receptors so as to activate a series of signal transmission processes and temporarily induce an increase in free Ca2+ in the cytoplasm, and a temporary increase in the intracellular calcium concentration gives rise to a temporary increase in the intracellular calcium concentration in various organs including, inter alia, those of the nervous system, cardiovascular system, endocrine system, reproductive system, digestive system and immune system where the LPA receptors are expressed, with physiological activity being exhibited.La présente invention concerne une glycolipoprotéine, la gintonine, isolée et identifiée à partir du ginseng, et utilisable en tant que ligand issu d'une plante médicinale naturelle agissant sur les récepteurs LPA1 (acide lysophosphatidique； 1- ou 2-acyl-sn-glycérol-3-phosphate), LPA2, LPA3, LPA4 et LPA5 dont l'efficacité est démontrée d'un point de vue physiologique/pharmaceutique par son interaction avec des récepteurs d'un sous-ensemble [LPA1(edg-2), LPA2(edg-4), LPA3(edg-7), LPA4, LPA5] de la famille EDG (gène de différentiation endothéliale) dans les récepteurs couplés à la protéine G (
